Ensign Peak Advisors
FATE icon

Ensign Peak Advisors’s Fate Therapeutics FATE Stock Holding History

Ensign Peak Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-123,750
Closed -$589K – 1758
2023
Q2 		$589K Buy
123,750
+24,300
+24% +$134K ﹤0.01% 1583
2023
Q1 		$567K Buy
99,450
+33,800
+51% +$204K ﹤0.01% 1612
2022
Q4 		$662K Buy
65,650
+45,400
+224% +$853K ﹤0.01% 1498
2022
Q3 		$454K Hold
20,250
– – ﹤0.01% 1510
2022
Q2 		$502K Hold
20,250
– – ﹤0.01% 1454
2022
Q1 		$785K Hold
20,250
– – ﹤0.01% 1337
2021
Q4 		$1.19M Buy
+20,250
New +$1.15M ﹤0.01% 1186
2021
Q3 		– Sell
-7,039
Closed -$611K – 1859
2021
Q2 		$611K Sell
7,039
-13,078
-65% -$1.05M ﹤0.01% 1559
2021
Q1 		$1.66M Sell
20,117
-12,617
-39% -$1.21M ﹤0.01% 1196
2020
Q4 		$2.98M Sell
32,734
-16,188
-33% -$1.01M 0.01% 836
2020
Q3 		$1.96M Buy
48,922
+43,740
+844% +$1.53M ﹤0.01% 984
2020
Q2 		$178K Hold
5,182
– – ﹤0.01% 1593
2020
Q1 		$115K Sell
5,182
-9,091
-64% -$230K ﹤0.01% 1568
2019
Q4 		$279K Buy
+14,273
New +$227K ﹤0.01% 1597

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ensign Peak Advisors's FATE Position: Q3 2023 in Review

Ensign Peak Advisors sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 123,750 shares — an estimated $589K sold.

Ensign Peak Advisors first reported a position in FATE in Q4 2019 and held it in 14 quarters. The position peaked at $2.98M in Q4 2020. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

  • Ensign Peak Advisors reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 123,750 Fate Therapeutics shares in Q3 2023, an estimated $589K.
  • Ensign Peak Advisors first reported a position in Fate Therapeutics in Q4 2019 and held it in 14 quarters.
  • Ensign Peak Advisors's Fate Therapeutics position peaked at $2.98M in Q4 2020.
  • 170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on Ensign Peak Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.